Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

VT1021

Peptide · Activator of thrombospondin 1 (THBS1)

Phase 2/3 Most advanced trial
1 Registered trials

What is VT1021?

VT1021 is a cyclic pentapeptide that activates thrombospondin 1 (TSP-1) expression in myeloid-derived suppressor cells within the tumor microenvironment. It stimulates anti-angiogenic and pro-apoptotic signaling through CD36 and CD47, while blocking CD47-mediated immune suppression to enhance macrophage activation and cytotoxic T-lymphocyte infiltration. It is studied in glioblastoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Peptide
Targets
thrombospondin 1 (THBS1), CD36 (secondary target), CD47 (secondary target)
Mechanism
Activator of thrombospondin 1 (THBS1)
Pathways
angiogenesis, apoptosis, macrophage activation, T-cell infiltration
Therapy area
Oncology
In trials of
BHVN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03970447 Phase 2/3 Glioblastoma Recruiting BHVN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Glioblastoma

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.